Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? - PubMed (original) (raw)

Review

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Samantha Turnbull et al. Viruses. 2015.

Abstract

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.

Keywords: HSV; clinical trials; immunotherapy; oncolytic virus; reovirus; vaccinia.

PubMed Disclaimer

Similar articles

• Virus combinations and chemotherapy for the treatment of human cancers.
  Kumar S, Gao L, Yeagy B, Reid T. Kumar S, et al. Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Curr Opin Mol Ther. 2008. PMID: 18683102 Review.
• Reovirus: viral therapy for cancer 'as nature intended'.
  Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Comins C, et al. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25. Clin Oncol (R Coll Radiol). 2008. PMID: 18583112 Review.
• Oncolytic virotherapy.
  Cervantes-García D, Ortiz-López R, Mayek-Pérez N, Rojas-Martínez A. Cervantes-García D, et al. Ann Hepatol. 2008 Jan-Mar;7(1):34-45. Ann Hepatol. 2008. PMID: 18376364 Review.
• Oncolytic vaccinia virus: from bedside to benchtop and back.
  Thorne SH. Thorne SH. Curr Opin Mol Ther. 2008 Aug;10(4):387-92. Curr Opin Mol Ther. 2008. PMID: 18683104
• Recent clinical experience with oncolytic viruses.
  Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. Donnelly OG, et al. Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. doi: 10.2174/138920112800958904. Curr Pharm Biotechnol. 2012. PMID: 21740364 Review.

Cited by

• Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses.
  Speranza MC, Kasai K, Lawler SE. Speranza MC, et al. ILAR J. 2016;57(1):63-72. doi: 10.1093/ilar/ilw002. ILAR J. 2016. PMID: 27034396 Free PMC article. Review.
• Oncolytic viruses as immunotherapy: progress and remaining challenges.
  Aurelian L. Aurelian L. Onco Targets Ther. 2016 May 4;9:2627-37. doi: 10.2147/OTT.S63049. eCollection 2016. Onco Targets Ther. 2016. PMID: 27226725 Free PMC article. Review.
• Real-time monitoring of oncolytic VSV properties in a novel in vitro microphysiological system containing 3D multicellular tumor spheroids.
  Lee KJ, Lee SW, Woo HN, Cho HM, Yu DB, Jeong SY, Joo CH, Jeong GS, Lee H. Lee KJ, et al. PLoS One. 2020 Jul 6;15(7):e0235356. doi: 10.1371/journal.pone.0235356. eCollection 2020. PLoS One. 2020. PMID: 32628693 Free PMC article.
• Repurposing the yellow fever vaccine for intratumoral immunotherapy.
  Aznar MA, Molina C, Teijeira A, Rodriguez I, Azpilikueta A, Garasa S, Sanchez-Paulete AR, Cordeiro L, Etxeberria I, Alvarez M, Rius-Rocabert S, Nistal-Villan E, Berraondo P, Melero I. Aznar MA, et al. EMBO Mol Med. 2020 Jan 9;12(1):e10375. doi: 10.15252/emmm.201910375. Epub 2019 Nov 19. EMBO Mol Med. 2020. PMID: 31746149 Free PMC article.
• Current understanding of reovirus oncolysis mechanisms.
  Phillips MB, Stuart JD, Rodríguez Stewart RM, Berry JT, Mainou BA, Boehme KW. Phillips MB, et al. Oncolytic Virother. 2018 Jun 14;7:53-63. doi: 10.2147/OV.S143808. eCollection 2018. Oncolytic Virother. 2018. PMID: 29942799 Free PMC article. Review.

References

1. 1. Moore A.E. Viruses with oncolytic properties and their adaptation to tumours. Ann. N. Y. Acad. Sci. 1952;54:945–952. doi: 10.1111/j.1749-6632.1952.tb39969.x. - DOI - PubMed
2. 1. Andtbacka R.H.I., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Agarwala S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 2015;33:2780–2788. doi: 10.1200/JCO.2014.58.3377. - DOI - PubMed
3. 1. Kanerva A., Nokisalmi P., Diaconu I., Koski A., Cerullo V., Liikanen I., Tähtinen S., Oksanen M., Heiskanen R., Pesonen S., et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res. 2013;19:2734–2744. doi: 10.1158/1078-0432.CCR-12-2546. - DOI - PubMed
4. 1. Morse M.A., Chaudhry A., Gabitzsch E.S., Hobeika A.C., Osada T., Clay T.M., Amalfitano A., Burnett B.K., Devi G.R., Hsu D.S., et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 2013;62:1293–1301. doi: 10.1007/s00262-013-1400-3. - DOI - PMC - PubMed
5. 1. Pesonen S., Diaconu I., Kangasniemi L., Ranki T., Kanerva A., Pesonen S.K., Gerdemann U., Leen A.M., Kairemo K., Oksanen M., et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients. Cancer Res. 2012;72:1621–1631. doi: 10.1158/0008-5472.CAN-11-3001. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • MDPI
  • PubMed Central
  • White Rose Research Online

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations